Back to Sites University of Pennsylvania Site Number ACTG 6201 Studies at this Site IMPAACT 2050: Phase IV Study of the Pharmacokinetics and Safety of Long-Acting Injectable Cabotegravir and Rilpivirine in Pregnant and Postpartum Women with HIV in the United States DAIDS Number 39208 Research Area Treatment Study Status In Development
IMPAACT 2050: Phase IV Study of the Pharmacokinetics and Safety of Long-Acting Injectable Cabotegravir and Rilpivirine in Pregnant and Postpartum Women with HIV in the United States DAIDS Number 39208 Research Area Treatment Study Status In Development
